http://purl.org/np/RAz7s2DG7q5YHxAe4acqg90lZufNiFPCHCSadN7U3mUWY#Head
http://purl.org/np/RAz7s2DG7q5YHxAe4acqg90lZufNiFPCHCSadN7U3mUWY
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RAz7s2DG7q5YHxAe4acqg90lZufNiFPCHCSadN7U3mUWY#assertion
http://purl.org/np/RAz7s2DG7q5YHxAe4acqg90lZufNiFPCHCSadN7U3mUWY
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RAz7s2DG7q5YHxAe4acqg90lZufNiFPCHCSadN7U3mUWY#provenance
http://purl.org/np/RAz7s2DG7q5YHxAe4acqg90lZufNiFPCHCSadN7U3mUWY
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RAz7s2DG7q5YHxAe4acqg90lZufNiFPCHCSadN7U3mUWY#pubinfo
http://purl.org/np/RAz7s2DG7q5YHxAe4acqg90lZufNiFPCHCSadN7U3mUWY
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RAz7s2DG7q5YHxAe4acqg90lZufNiFPCHCSadN7U3mUWY#assertion
http://purl.obolibrary.org/obo/DOID_4450
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RAz7s2DG7q5YHxAe4acqg90lZufNiFPCHCSadN7U3mUWY#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_4450
http://purl.org/np/RAz7s2DG7q5YHxAe4acqg90lZufNiFPCHCSadN7U3mUWY#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RAz7s2DG7q5YHxAe4acqg90lZufNiFPCHCSadN7U3mUWY#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB01268
http://purl.org/np/RAz7s2DG7q5YHxAe4acqg90lZufNiFPCHCSadN7U3mUWY#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RAz7s2DG7q5YHxAe4acqg90lZufNiFPCHCSadN7U3mUWY#association
http://www.w3.org/2000/01/rdf-schema#label
sutent is a kinase inhibitor indicated for the treatment of gastrointestinal stromal tumor gist after disease progression on or intolerance to imatinib mesylate 1 1 the treatment of advanced renal cell carcinoma rcc 1 2 the adjuvant treatment of adult patients at high risk of recurrent rcc following nephrectomy 1 3 the treatment of progressive well differentiated pancreatic neuroendocrine tumors pnet in patients with unresectable locally advanced or metastatic disease 1 4 sutent is indicated for the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate sutent is indicated for the treatment of advanced renal cell carcinoma sutent is indicated for the adjuvant treatment of adult patients at high risk of recurrent rcc following nephrectomy sutent is indicated for the treatment of progressive well differentiated pancreatic neuroendocrine tumors in patients with unresectable locally advanced or metastatic disease
http://purl.org/np/RAz7s2DG7q5YHxAe4acqg90lZufNiFPCHCSadN7U3mUWY#association
https://w3id.org/biolink/vocab/association_type
https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation
http://purl.org/np/RAz7s2DG7q5YHxAe4acqg90lZufNiFPCHCSadN7U3mUWY#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RAz7s2DG7q5YHxAe4acqg90lZufNiFPCHCSadN7U3mUWY#association
https://w3id.org/biolink/vocab/relation
https://schema.org/TreatmentIndication
https://identifiers.org/drugbank:DB01268
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RAz7s2DG7q5YHxAe4acqg90lZufNiFPCHCSadN7U3mUWY#provenance
http://purl.org/np/RAz7s2DG7q5YHxAe4acqg90lZufNiFPCHCSadN7U3mUWY#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAz7s2DG7q5YHxAe4acqg90lZufNiFPCHCSadN7U3mUWY#pubinfo
http://purl.org/np/RAz7s2DG7q5YHxAe4acqg90lZufNiFPCHCSadN7U3mUWY#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RAz7s2DG7q5YHxAe4acqg90lZufNiFPCHCSadN7U3mUWY#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RAz7s2DG7q5YHxAe4acqg90lZufNiFPCHCSadN7U3mUWY#sig
http://purl.org/nanopub/x/hasSignature
IbmxHLDhkLeZ/iUe35feVHnJ++MfzrsM6Y5xa+lPm7jX1M8IyZo99G/LnVLL3f4trWSzYfQLGPzMyUvYJ556I+yoTH6OB5seG+1TxbbdxHMzBnUDD2a/6qkfce7i1oIikxZVyXDQe/5+A92FzH2iPnTu2mcoye7eTyviIILLzVs=
http://purl.org/np/RAz7s2DG7q5YHxAe4acqg90lZufNiFPCHCSadN7U3mUWY#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RAz7s2DG7q5YHxAe4acqg90lZufNiFPCHCSadN7U3mUWY
http://purl.org/np/RAz7s2DG7q5YHxAe4acqg90lZufNiFPCHCSadN7U3mUWY
http://purl.org/dc/terms/created
2021-07-03T11:43:08.227+02:00
http://purl.org/np/RAz7s2DG7q5YHxAe4acqg90lZufNiFPCHCSadN7U3mUWY
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAz7s2DG7q5YHxAe4acqg90lZufNiFPCHCSadN7U3mUWY
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RAz7s2DG7q5YHxAe4acqg90lZufNiFPCHCSadN7U3mUWY
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RAz7s2DG7q5YHxAe4acqg90lZufNiFPCHCSadN7U3mUWY
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs